Do immunotherapy and ß cell replacement play a synergistic role in the treatment of type 1 diabetes?

Li, Dongsheng; Warnock, Garth L.; Tu, Han-Jun; Ao, Ziliang; He, Zehua; Lü, Hong

doi:10.1016/j.lfs.2009.08.016

Cited by 16 publications

(8 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is worth mentioning that the expression of MHC I and MHC II in undifferentiated MSCs could be proportionally increased with the differentiation extent of MSCs. 123 The therapeutic benefit of MSC transplantation in various disorders characterized by cell injury or cell loss are shown in some recent studies such as myocardial infarction, 124,125 traumatic brain injury, [126][127][128] Parkinson's disease, 129 type 1 diabetes, 94,130,131 and liver disease. 132 Lately, with the discovery of MSCs' tumor tropism, much interest is dedicated to determining the role MSCs could have in cancer therapy.…”

Section: Mscs In Therapeuticsmentioning

confidence: 99%

“…161 In addition, inhibition of lymphocyte proliferation and suppression of the immune function of effector T lymphocytes (T eff ), such as: CD4 þ and CD8 þ T cells, B cells, and natural killer cells have been observed by MSCs. 131,162 The interaction and influence of MSCs on the immune system has proven to be more complex than previously thought, and it appears that this could be attributed to direct cell interactions between MSCs and other soluble factors that are released from MSCs.…”

Section: Immunosuppressionmentioning

confidence: 99%

See 1 more Smart Citation

The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells

2014

Cancer Gene Ther

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have attracted significant attention in cancer research as a result of their accessibility, tumor-oriented homing capacity, and the feasibility of auto-transplantation. This review provides a comprehensive overview of current challenges in pancreatic cancer therapy, and we propose a novel strategy for using MSCs as means of delivering anticancer genes to the site of pancreas. We aim to provide a practical platform for the development of MSC-based therapy for pancreatic cancer.

show abstract

Section: Mscs In Therapeuticsmentioning

confidence: 99%

Section: Immunosuppressionmentioning

confidence: 99%

The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells

2014

Cancer Gene Ther

View full text Add to dashboard Cite

show abstract

“…In addition, the immunosuppressive capacity of MSC may also be mediated by the secretion of soluble factors, and by the induction of T-cell anergy and regulatory T-cells (Tregs), with important consequences for treatment, e.g. improvement of current tolerization strategies using anti-CD3 antibodies [20,21]. Recent studies demonstrated that the secretion of key soluble factors is not a constitutive process: secretion is often a consequence of cross-talk between MSC and T-lymphocytes, the latter being able to trigger this de novo expression [22].…”

Section: Msc Immnomodulatory Properties In Vitro and In Vivomentioning

confidence: 99%

Wharton’s Jelly Mesenchymal Stem Cells as Candidates for Beta Cells Regeneration: Extending the Differentiative and Immunomodulatory Benefits of Adult Mesenchymal Stem Cells for the Treatment of Type 1 Diabetes

Anzalone

Iacono

Loria

et al. 2010

Stem Cell Rev and Rep

128

View full text Add to dashboard Cite

Mesenchymal stem cells (MSC) are uniquely capable of crossing germinative layers borders (i.e. are able to differentiate towards ectoderm-, mesoderm- and endoderm-derived cytotypes) and are viewed as promising cells for regenerative medicine approaches in several diseases. Type I diabetes therapy should potentially benefit from such differentiated cells: the search for alternatives to organ/islet transplantation strategies via stem cells differentiation is an ongoing task, significant goals having been achieved in most experimental settings (e.g. insulin production and euglycaemia restoration), though caution is still needed to ensure safe and durable effects in vivo. MSC are obtainable in high numbers via ex vivo culture and can be differentiated towards insulin-producing cells (IPC). Moreover, recent reports evidenced that MSC possess immunomodulatory activities (acting on both innate and acquired immunity effectors) which should result in a reduction of the immunogenicity of transplanted cells, thus limiting rejection. Moreover it has been proposed that MSC administration should be used to attenuate the autoimmune processes which lead to the destruction of beta cells. This review illustrates the recent advances made in differentiating human MSC to IPC. In particular, we compare the effectiveness of the differentiation protocols applied, the markers and functional assays used to characterize differentiated progeny, and the in vivo controls. We further speculate on how MSC derived from Wharton's jelly of human umbilical cord may represent a more promising regenerative medicine tool, as recently demonstrated for endoderm-derived organs (as liver) in human subjects, also considering their peculiar immunomodulatory features compared to other MSC populations.

show abstract

“…The mechanisms underlying immunomodulation by MSCs are different: suppression of T cell proliferation and dendritic cell differentiation [42], inhibition of B-cells [43], and natural killer cells (NK) proliferation [44], induction of T cells anergy and stimulation of regulatory T cells (CD4+CD25+FoxP3+ T regs) [45,46].…”

Section: Immunomodulatory Properties and Tolerogenic Activity By Mscsmentioning

confidence: 99%

Human Wharton's Jelly Mesenchymal Stem Cells Maintain the Expression of Key Immunomodulatory Molecules When Subjected to Osteogenic, Adipogenic and Chondrogenic Differentiation In Vitro: New Perspectives for Cellular Therapy

Rocca¹,

Iacono²,

Corsello³

et al. 2013

CSCR

View full text Add to dashboard Cite

Rheumatoid arthritis and osteoarthritis are the main diseases that imply an inflammatory process at the joints involving the articular cartilage. Recently, mesenchymal stem cells (MSCs) derived from perinatal tissues were considered good candidates for cellular therapy of musculoskeletal and orthopaedic diseases, since they can differentiate into multiple cell types and are an easily accessible cellular source. Therefore, several protocols exist on the differentiation of mesenchymal stem cells of different origins into osteoblasts and chondrocytes. Another key feature of MSCs is their capacity to modulate the immune system responses in vitro and in vivo. This may have critical outcomes in diseases of the musculoskeletal system where an inflammatory or autoimmune process is at the basis of the main disease.In the present paper, after isolation of MSCs from Wharton's Jelly (WJ-MSCs), we performed the three standard differentiation protocols. The acquisition of the differentiated phenotype was demonstrated by the specific histological stains. As the main objective of this work, we determined the expression of immunomodulatory molecules (by immunohistochemistry and qualitative RT-PCR), both in undifferentiated cells and after differentiation. We demonstrated for the first time that immune-related molecules (as B7-H3/CD276 and HLA-E) which have been characterized in undifferentiated MSCs, are also expressed by the differentiated progeny. This strongly suggests that also after the acquisition of a mature phenotype, WJ-MSCs-derived cells may maintain their immune privilege. This evidence, which deserves much work to be confirmed in vivo and in other MSCs populations, may provide a formal proof of the good results globally achieved with WJMSCs as cellular therapy vehicle.

show abstract

Do immunotherapy and ß cell replacement play a synergistic role in the treatment of type 1 diabetes?

Cited by 16 publications

References 83 publications

The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells

The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells

Wharton’s Jelly Mesenchymal Stem Cells as Candidates for Beta Cells Regeneration: Extending the Differentiative and Immunomodulatory Benefits of Adult Mesenchymal Stem Cells for the Treatment of Type 1 Diabetes

Human Wharton's Jelly Mesenchymal Stem Cells Maintain the Expression of Key Immunomodulatory Molecules When Subjected to Osteogenic, Adipogenic and Chondrogenic Differentiation In Vitro: New Perspectives for Cellular Therapy

Contact Info

Product

Resources

About